• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在不同透析液和超滤流速下进行持续肾脏替代治疗时的扩散性和对流性溶质清除率。

Diffusive and convective solute clearances during continuous renal replacement therapy at various dialysate and ultrafiltration flow rates.

作者信息

Brunet S, Leblanc M, Geadah D, Parent D, Courteau S, Cardinal J

机构信息

Intensive Care Units, Maisonneuve-Rosemont Hospital, Montreal, Canada.

出版信息

Am J Kidney Dis. 1999 Sep;34(3):486-92. doi: 10.1016/s0272-6386(99)70076-4.

DOI:10.1016/s0272-6386(99)70076-4
PMID:10469859
Abstract

Clearances of several solutes (urea, creatinine, phosphate, urates, beta(2)-microglobulin [beta(2)-M]) were measured during venovenous continuous renal replacement therapy (CRRT) at various ultrafiltration (Q(UF); 0 to 2 L/h) and dialysate flow rates (Q(D); 0 to 2.5 L/h). Preset Multiflow-60 and Multiflow-100 hollow-fiber dialysers (M-60 and M-100; Hospal-Gambro, St-Leonard, Canada) were compared (five patients for each type). First, we evaluated the impact of predilution on convective clearances: a progressive decrease in patient clearances, similar for both filters, was observed, reaching a maximum of 15%, 18%, and 19% for urea, urates, and creatinine, respectively, with predilution at a Q(UF) of 2 L/h. Second, we compared convective and diffusive clearances. Because effluent to plasma ratio (E/P) remained at 1 for small solutes (urea, creatinine, phosphate, urates) during convection, clearances were equal to the effluent rate for both dialyzers. However, we observed greater diffusive clearances for small molecules with M-100 than with M-60 at a Q(D) of 1.5 to 2.5 L/h, the difference being more significant as molecular weight increased. For beta(2)-M, diffusive clearance was very low and rapidly reached a plateau of 8 and 12 mL/min for M-60 and M-100, respectively, at a Q(D) greater than 1.5 L/h. Convective clearances for beta(2)-M increased nonlinearly up to 20 +/- 2 mL/min at a progressively greater Q(UF) (from 0.5 to 2 L/h) for both M-60 and M-100. This nonlinear increase was attributed to an increase of almost 40% in E/P for beta(2)-M from a Q(UF) of 0.5 to 2 L/h. Third, the interaction between convection and diffusion was assessed by measuring solute clearances at a fixed Q(UF) (1 and 2 L/h) and variable Q(D) (0.5 to 2.5 L/h). For small molecules, no significant interaction between convection and diffusion was noticed with M-100, whereas only a small interaction was noticed with M-60. However, for beta(2)-M, the addition of diffusion (Q(D), 0.5 to 2.5 L/h) did not result in any significant increase in total clearances over convective clearances for M-60 and M-100. This observation suggests that the diffusive clearances for beta(2)-M observed with M-60 and M-100 at a Q(UF) of 0 L/h and at various Q(D) probably occurs by convective fluxes across the membrane. These results demonstrate that convection is more efficient than diffusion in removing mixed-molecular-weight solutes during CRRT.

摘要

在静脉 - 静脉连续性肾脏替代治疗(CRRT)期间,于不同超滤率(Q(UF);0至2L/h)和透析液流速(Q(D);0至2.5L/h)下,测量了几种溶质(尿素、肌酐、磷酸盐、尿酸盐、β2 - 微球蛋白[β2 - M])的清除率。比较了预设的Multiflow - 60和Multiflow - 100中空纤维透析器(M - 60和M - 100;加拿大圣莱昂纳德市Hospal - Gambro公司)(每种类型各5例患者)。首先,我们评估了预稀释对对流清除率的影响:观察到患者清除率逐渐下降,两种滤器情况相似,在Q(UF)为2L/h进行预稀释时,尿素、尿酸盐和肌酐的清除率分别最多下降15%、18%和19%。其次,我们比较了对流清除率和扩散清除率。由于在对流过程中小溶质(尿素、肌酐、磷酸盐、尿酸盐)的流出液与血浆比率(E/P)保持为1,两种透析器的清除率均等于流出液速率。然而,我们观察到在Q(D)为1.5至2.5L/h时,M - 100对小分子的扩散清除率高于M - 60,且随着分子量增加差异更显著。对于β2 - M,扩散清除率非常低,在Q(D)大于1.5L/h时,M - 60和M - 100的扩散清除率分别迅速达到8和12mL/min的平台值。对于M - 60和M - 100,随着Q(UF)逐渐增大(从0.5至2L/h),β2 - M的对流清除率非线性增加至20±2mL/min。这种非线性增加归因于β2 - M的E/P从Q(UF)为0.5L/h增加到2L/h时几乎增加了40%。第三,通过在固定Q(UF)(1和2L/h)和可变Q(D)(0.5至2.5L/h)下测量溶质清除率来评估对流与扩散之间的相互作用。对于小分子,M - 100未观察到对流与扩散之间有显著相互作用,而M - 60仅观察到轻微相互作用。然而,对于β2 - M,对于M - 60和M - 100,增加扩散(Q(D)为0.5至2.5L/h)并未导致总清除率相对于对流清除率有任何显著增加。这一观察结果表明,在Q(UF)为0L/h和不同Q(D)时,M - 60和M - 100观察到的β2 - M的扩散清除率可能是通过跨膜对流通量发生的。这些结果表明,在CRRT期间,对流在清除混合分子量溶质方面比扩散更有效。

相似文献

1
Diffusive and convective solute clearances during continuous renal replacement therapy at various dialysate and ultrafiltration flow rates.在不同透析液和超滤流速下进行持续肾脏替代治疗时的扩散性和对流性溶质清除率。
Am J Kidney Dis. 1999 Sep;34(3):486-92. doi: 10.1016/s0272-6386(99)70076-4.
2
[The effects of dialysate and ultrafiltration flow rate on solute clearance during continuous renal replacement therapy].[透析液和超滤流速对连续性肾脏替代治疗期间溶质清除率的影响]
Zhonghua Nei Ke Za Zhi. 2001 Mar;40(3):183-6.
3
Solute clearances during continuous venovenous haemofiltration at various ultrafiltration flow rates using Multiflow-100 and HF1000 filters.使用Multiflow - 100和HF1000滤器在不同超滤流速下进行持续静脉 - 静脉血液滤过时的溶质清除率。
Nephrol Dial Transplant. 2003 May;18(5):961-6. doi: 10.1093/ndt/gfg055.
4
Myoglobin clearance and removal during continuous venovenous hemofiltration.持续静脉-静脉血液滤过过程中肌红蛋白的清除与去除
Intensive Care Med. 1999 Oct;25(10):1169-72. doi: 10.1007/s001340051031.
5
Mixed predilution and postdilution online hemodiafiltration compared with the traditional infusion modes.混合预稀释和后稀释在线血液透析滤过与传统输注模式的比较。
Kidney Int. 2000 Nov;58(5):2155-65. doi: 10.1111/j.1523-1755.2000.00389.x.
6
The clearance of protein-bound solutes by hemofiltration and hemodiafiltration.血液滤过和血液透析滤过对蛋白结合溶质的清除作用。
Kidney Int. 2005 Aug;68(2):867-77. doi: 10.1111/j.1523-1755.2005.00469.x.
7
Comparison of solute clearance in three modes of continuous renal replacement therapy.三种连续性肾脏替代治疗模式下溶质清除率的比较。
Pediatr Crit Care Med. 2004 May;5(3):269-74. doi: 10.1097/01.pcc.0000123554.12555.20.
8
On-line hemodiafiltration with pre- and postdilution: a comparison of efficacy.前后稀释的在线血液透析滤过:疗效比较
Int J Artif Organs. 1997 Feb;20(2):81-90.
9
CVVHD treatment with CARPEDIEM: small solute clearance at different blood and dialysate flows with three different surface area filter configurations.使用CARPEDIEM进行连续性静脉-静脉血液透析滤过治疗:三种不同表面积滤器配置下不同血液和透析液流速时的小分子溶质清除率
Pediatr Nephrol. 2016 Oct;31(10):1659-65. doi: 10.1007/s00467-016-3397-2. Epub 2016 Apr 30.
10
Solute transport in continuous hemodialysis: a new treatment for acute renal failure.连续性血液透析中的溶质转运:急性肾衰竭的一种新疗法。
Kidney Int. 1987 Oct;32(4):562-71. doi: 10.1038/ki.1987.245.

引用本文的文献

1
The Urea-Creatinine Ratio as Marker of Catabolism Is Affected by Continuous Renal Replacement Therapy.作为分解代谢标志物的尿素-肌酐比值受连续性肾脏替代治疗的影响。
Diagnostics (Basel). 2025 Jun 1;15(11):1408. doi: 10.3390/diagnostics15111408.
2
Comparison of Different Membranes for Continuous Renal Replacement Therapies: An In Vitro Study.不同膜用于连续性肾脏替代治疗的比较:一项体外研究
ASAIO J. 2025 Jun 1;71(6):510-518. doi: 10.1097/MAT.0000000000002387. Epub 2025 Feb 5.
3
Early and high-volume administration of sodium bicarbonate in sepsis-associated acute kidney injury in patients with malignancies, during continuous renal replacement therapy.
在接受连续性肾脏替代治疗的恶性肿瘤患者脓毒症相关性急性肾损伤中早期大剂量给予碳酸氢钠
Ren Fail. 2025 Dec;47(1):2443026. doi: 10.1080/0886022X.2024.2443026. Epub 2025 Jan 13.
4
The Clearance of Midazolam and Metabolites during Continuous Renal Replacement Therapy in Critically Ill Patients with COVID-19.COVID-19 危重症患者连续性肾脏替代治疗期间咪达唑仑及其代谢物的清除率。
Blood Purif. 2024;53(2):107-113. doi: 10.1159/000534538. Epub 2023 Nov 3.
5
Management of Poisonings and Intoxications.中毒与药物过量的处理。
Clin J Am Soc Nephrol. 2023 Sep 1;18(9):1210-1221. doi: 10.2215/CJN.0000000000000057. Epub 2023 Jan 13.
6
Timing of kidney replacement therapy initiation for acute kidney injury.急性肾损伤患者肾脏替代治疗时机的选择。
Cochrane Database Syst Rev. 2022 Nov 23;11(11):CD010612. doi: 10.1002/14651858.CD010612.pub3.
7
How To Prescribe And Troubleshoot Continuous Renal Replacement Therapy: A Case-Based Review.如何开具和解决连续肾脏替代治疗处方:基于案例的复习。
Kidney360. 2020 Dec 14;2(2):371-384. doi: 10.34067/KID.0004912020. eCollection 2021 Feb 25.
8
Serum Albumin Before CRRT Was Associated With the 28- and 90-Day Mortality of Critically Ill Patients With Acute Kidney Injury and Treated With Continuous Renal Replacement Therapy.连续性肾脏替代治疗前的血清白蛋白水平与接受连续性肾脏替代治疗的急性肾损伤重症患者的28天及90天死亡率相关。
Front Nutr. 2021 Aug 25;8:717918. doi: 10.3389/fnut.2021.717918. eCollection 2021.
9
A Clinician's Guide to Dosing Analgesics, Anticonvulsants, and Psychotropic Medications in Continuous Renal Replacement Therapy.《连续性肾脏替代治疗中镇痛药、抗惊厥药和精神药物给药的临床医生指南》
Kidney Int Rep. 2021 May 13;6(8):2033-2048. doi: 10.1016/j.ekir.2021.05.004. eCollection 2021 Aug.
10
Dose of Continuous Renal Replacement Therapy in Critically Ill Patients: A Bona Fide Quality Indicator.危重症患者连续性肾脏替代治疗剂量:一个名副其实的质量指标。
Nephron. 2021;145(2):91-98. doi: 10.1159/000512846. Epub 2021 Feb 4.